Ind Swift Laboratories Ltd vs Speciality Medicines Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Ind-Swift Laboratories Ltd is ₹ 144.45 as of 06 May 15:30 . The P/E Ratio of Ind-Swift Laboratories Ltd changed from 6.9 on March 2023 to 2.3 on March 2025 . This represents a CAGR of -30.66% over 3 yearsThe P/E Ratio of Speciality Medicines Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Ind-Swift Laboratories Ltd changed from ₹ 425.72 crore on March 2021 to ₹ 509.08 crore on March 2025 . This represents a CAGR of 3.64% over 5 yearsThe Market Cap of Speciality Medicines Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Ind-Swift Laboratories Ltd for the Dec '25 is ₹ 178.43 crore as compare to the Sep '25 revenue of ₹ 170.5 crore. This represent the growth of 4.65% The revenue of Speciality Medicines Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Ind-Swift Laboratories Ltd for the Dec '25 is ₹ 25.9 crore as compare to the Sep '25 ebitda of ₹ 19.34 crore. This represent the growth of 33.92% The ebitda of Speciality Medicines Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Ind-Swift Laboratories Ltd changed from ₹ 1.01 crore to ₹ 9.52 crore over 7 quarters. This represents a CAGR of 260.37% The net profit of Speciality Medicines Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Ind-Swift Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Speciality Medicines Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Limited is a part of the Ind-Swift Group and is based at Chandigarh, Punjab, India.
The Company is one of the leading manufacturers of APIs catering to global and domestic formulators.
Based in Chandigarh, India, the Company operated two advanced manufacturing facilities in Derabassi and Jammu, adhering to international standards.
Ind-Swift Laboratories Ltd. is recognised globally as a leader in the Macrolide Antibiotic sector, and its products are well-regarded by major pharmaceutical formulators worldwide. Ind-Swift Laboratories Limited was incorporated on January 4, 1995 as a joint venture between Ind-Swift Ltd and Punjab State Industrial Development Corporation.
Later, Ind-Swift purchased Punjab State Industrial Development Corporation equity to emerge as a single largest shareholder in the company.

About Speciality Medicines Ltd

Speciality Medicines Limited was originally incorporated as 'Speciality Medicines Private Limited' as a Private Limited Company, dated February 05, 2021, issued by the Registrar of Companies, Central Registration Centre.
Later on, the status was converted to Public Limited and the name of the Company was changed to 'Speciality Medicines Limited' and a fresh Certificate of Incorporation dated June 25, 2024 was issued to the Company by Registrar of Companies. The Company is engaged in marketing & distribution of finished formulations of Specialty pharmaceuticals - high-cost oral or injectable medications used to treat complex chronic conditions in Domestic as well as International Market.
The Company has presence over 35 countries. The Company deal in Specialty pharmaceuticals finished formulations Capsules, Cream, Eye Drops, Gel, Infusion, Inhalation, Inhaler, Injection, Nasal Spray, Ointment, Ophthalmic, Oral Solution, Oral Suspension, Sachet, Suspension and Tablet.

FAQs for the comparison of Ind-Swift Laboratories Ltd and Speciality Medicines Ltd

Which company has a larger market capitalization, Ind-Swift Laboratories Ltd or Speciality Medicines Ltd?

Market cap of Ind-Swift Laboratories Ltd is 1,254 Cr while Market cap of Speciality Medicines Ltd is 277 Cr

What are the key factors driving the stock performance of Ind-Swift Laboratories Ltd and Speciality Medicines Ltd?

The stock performance of Ind-Swift Laboratories Ltd and Speciality Medicines Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Ind-Swift Laboratories Ltd and Speciality Medicines Ltd?

As of May 6, 2026, the Ind-Swift Laboratories Ltd stock price is INR ₹144.45. On the other hand, Speciality Medicines Ltd stock price is INR ₹316.2.

How do dividend payouts of Ind-Swift Laboratories Ltd and Speciality Medicines Ltd compare?

To compare the dividend payouts of Ind-Swift Laboratories Ltd and Speciality Medicines Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.